Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra Wendler

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Steroids|September 29, 2009
Translational research on rapid steroid actionsAlexandra Wendler, Martin Wehling
Trends in Endocrinology and Metabolism: TEM|November 17, 2022
Many or too many progesterone membrane receptors? Clinical implicationsAlexandra Wendler, Martin Wehling
European Journal of Clinical Pharmacology|June 6, 2023
Translatability scoring in prospective and retrospective COVID drug development casesAlexandra Wendler, Martin Wehling
Hypertension (Dallas, Tex. : 1979)|March 23, 2011
Is GPR30 the membrane aldosterone receptor postulated 20 years ago?Alexandra Wendler, Martin Wehling
Steroids|January 2, 2013
PGRMC2, a yet uncharacterized protein with potential as tumor suppressor, migration inhibitor, and regulator of cytochrome P450 enzyme activityAlexandra Wendler, Martin Wehling
Current Opinion in Pharmacology|June 15, 2010
The translatability of animal models for clinical development: biomarkers and disease modelsAlexandra Wendler, Martin Wehling
Journal of Translational Medicine|March 9, 2012
Translatability scoring in drug development: eight case studiesAlexandra Wendler, Martin Wehling
Journal of Translational Medicine|November 5, 2017
Translatability score revisited: differentiation for distinct disease areasAlexandra Wendler, Martin Wehling
Steroids|January 31, 2012
Nongenomic actions of aldosterone and progesterone revisitedAlexandra Wendler, Christian Albrecht, Martin Wehling
Steroids|October 16, 2012
In vitro inhibition of SKOV-3 cell migration as a distinctive feature of progesterone receptor membrane component type 2 versus type 1Christian Albrecht, Volker Huck, Martin Wehling, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Steroids|September 29, 2009
Translational research on rapid steroid actionsAlexandra Wendler, Martin Wehling
Trends in Endocrinology and Metabolism: TEM|November 17, 2022
Many or too many progesterone membrane receptors? Clinical implicationsAlexandra Wendler, Martin Wehling
European Journal of Clinical Pharmacology|June 6, 2023
Translatability scoring in prospective and retrospective COVID drug development casesAlexandra Wendler, Martin Wehling
Hypertension (Dallas, Tex. : 1979)|March 23, 2011
Is GPR30 the membrane aldosterone receptor postulated 20 years ago?Alexandra Wendler, Martin Wehling
Steroids|January 2, 2013
PGRMC2, a yet uncharacterized protein with potential as tumor suppressor, migration inhibitor, and regulator of cytochrome P450 enzyme activityAlexandra Wendler, Martin Wehling
Current Opinion in Pharmacology|June 15, 2010
The translatability of animal models for clinical development: biomarkers and disease modelsAlexandra Wendler, Martin Wehling
Journal of Translational Medicine|March 9, 2012
Translatability scoring in drug development: eight case studiesAlexandra Wendler, Martin Wehling
Journal of Translational Medicine|November 5, 2017
Translatability score revisited: differentiation for distinct disease areasAlexandra Wendler, Martin Wehling
Steroids|January 31, 2012
Nongenomic actions of aldosterone and progesterone revisitedAlexandra Wendler, Christian Albrecht, Martin Wehling
Steroids|October 16, 2012
In vitro inhibition of SKOV-3 cell migration as a distinctive feature of progesterone receptor membrane component type 2 versus type 1Christian Albrecht, Volker Huck, Martin Wehling, et al.
Pageof 2